Sidoti Csr Weighs in on Kamada’s Q2 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA) – Sidoti Csr increased their Q2 2025 earnings per share estimates for Kamada in a research report issued to clients and investors on Monday, March 3rd. Sidoti Csr analyst J. Sidoti now anticipates that the biotechnology company will post earnings of $0.08 per share for the quarter, up from their previous estimate of $0.07. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. Sidoti Csr also issued estimates for Kamada’s Q3 2025 earnings at $0.08 EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Kamada in a research report on Friday, January 10th.

Kamada Price Performance

Shares of NASDAQ KMDA opened at $6.79 on Tuesday. Kamada has a one year low of $4.74 and a one year high of $9.15. The business’s fifty day moving average price is $7.03 and its 200-day moving average price is $6.12. The stock has a market capitalization of $390.29 million, a PE ratio of 24.25, a P/E/G ratio of 0.97 and a beta of 0.99.

Institutional Trading of Kamada

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Plato Investment Management Ltd bought a new position in Kamada in the 3rd quarter worth about $117,000. Public Employees Retirement System of Ohio bought a new position in Kamada in the 3rd quarter worth about $77,000. JPMorgan Chase & Co. bought a new position in Kamada in the 4th quarter worth about $67,000. NewEdge Advisors LLC increased its stake in Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 8,260 shares during the last quarter. Finally, Aristides Capital LLC increased its stake in Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after acquiring an additional 6,850 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.